Citations

Clear

862 citation(s) found for "Habermann, EB".

Single‐agent lenalidomide is active in patients with relapsed or refractory aggressive non‐Hodgkin lymphoma who received prior stem cell transplantation
Czuczman, Myron S., Zinzani, Pier Luigi , Reeder, Craig B. , Tuscano, Joseph M. , Lossos, Izidore S. , Pietronigro, Dennis, Vose, Julie M. , Habermann, Thomas M. , Li, Ju , Witzig, Thomas E. , Zinzani, Pier Luigi

Mayo Clinic

British Journal of Haematology | July 9, 2013 | Volume: 162 | Issue: 5 | Pages: 639-647

10.1111/bjh.12449 | PMID 23834234 Get It

SummaryPatients with aggressive non‐Hodgkin lymphoma (NHL) who relapse after autologous stem cell transplantation (ASCT) have a poor prognosis. Additional therapy is often poorly tolerated, and new treatment modalities are needed. This efficacy and safety study was a retrospective analysis of two phase II trials (NHL‐002 and NHL‐003) that studied single‐agent lenalidomide in patients with relapsed/refractory aggressive NHL with prior (n = 87) compared with no prior ASCT (n = 179). The overall response rate in the ASCT group was 39% [14% complete response (CR)], including 29% in patients with diffuse large B‐cell lymphoma, 63% in mantle cell lymphoma, and 60% in transformed lymphoma. The timing of transplant relative to receiving lenalidomide had no effect on outcomes. Median progression‐free survival for the ASCT group was 3·7 months (16·9 months for patients in CR; 7·3 months for partial responders) at a median 12·5‐month follow‐up. Median response duration was 7·9 months. Regardless of prior ASCT, lenalidomide monotherapy was efficacious in heavily pretreated patients with aggressive, relapsed/refractory NHL, with a safety profile that was consistent with prior studies of single‐agent lenalidomide.
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma
Wiseman, Gregory A., Maurer, Matthew J. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Inwards, David J. , Porrata, Luis F. , Link, Brian K. , Johnston, Patrick B. , Allmer, Cristine, Asmann, Yan W. , Ballas, Zuhair K. , Smith, Brian J., Weiner, George J. , Witzig, Thomas E. , Habermann, Thomas M. , Colgan, Joseph P. , Zent, Clive S. , Shanafelt, Tait D. , Gupta, Mamta , Smith, Brian J., Maurer, Matthew , Link, Brian K , Weiner, George

Mayo Clinic

American Journal of Hematology | April 26, 2013 | Volume: 88 | Issue: 7 | Pages: 589-593

10.1002/ajh.23460 | PMID 23619698 Get It

Radioimmunotherapy (RIT) for relapsed indolent non‐Hodgkin lymphoma produces overall response rates (ORR) of 80% with mostly partial remissions. Synthetic CpG oligonucleotides change the phenotype of malignant B‐cells, are immunostimulatory, and can produce responses when injected intratumorally and combined with conventional radiation. In this phase I trial, we tested systemic administration of both CpG and RIT. Eligible patients had biopsy‐proven previously treated CD20+ B‐cell NHL and met criteria for RIT. Patients received rituximab 250 mg/m2 days 1,8, and 15; 111In‐ibritumomab tiuxetan days 1, 8; CpG 7909 days 6, 13, 20, 27; and 0.4 mCi/kg of 90Y‐ibritumomab tiuxetan day 15. The doses of CpG 7909 tested were 0.08, 0.16, 0.32 (six patients each) and 0.48 mg/kg (12 patients) IV over 2 hr without dose limiting toxicity. The ORR was 93% (28/30) with 63% (19/30) complete remission (CR); median progression free survival of 42.7 months (95% CI 18‐NR); and median duration of response (DR) of 35 months (4.6–76+). Correlative studies demonstrated a decrease in IL10 and TNFα, and an increase in IL1β, in response to therapy. CpG 7909 at a dose of 0.48 mg/kg is safe with standard RIT and produces a high CR rate and long DR; these results warrant confirmation. Am. J. Hematol. 88:589–593, 2013. © 2013 Wiley Periodicals, Inc.
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein–Barr virus status
Ghesquières, Hervé , Link, Brian K. , Maurer, Matthew J. , Cunningham, Julie M. , Novak, Anne J. , Larrabee, Beth R. , Allmer, Cristine, Ansell, Stephen M. , Cerhan, James R. , Doǧan, Ahmet , Slager, Susan L. , Habermann, Thomas M. , Maurer, Matthew , Cerhan, James R , Link, Brian K

Mayo Clinic

Leukemia & Lymphoma | April 19, 2013 | Volume: 54 | Issue: 11 | Pages: 2571-2573

10.3109/10428194.2013.796048 | PMID 23597143 Get It

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Choquet, Sylvain , Jagadeesh, Deepa , Smith, Sonali M. , Leblond, V., Roy, Rupali, Gordon, Leo I. , Dierickx, Daan , Schiff, David , Evens, Andrew M. , Kroll‐Desrosiers, Aimee , Morschhauser, Franck , BARTON, BRUCE A. , Gandhi, Maher K. , Habermann, Thomas M. , Trappe, Ralf Ulrich , Gordon, Leo I

Mayo Clinic

American Journal of Transplantation | April 3, 2013 | Volume: No volume available | Issue: No issue available | Pages: n/a-n/a

10.1002/ajt.12211 Get It

A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region
Cerhan, James R. , Fredericksen, Zachary S., Novak, Anne J. , Ansell, Stephen M. , Liebow, Mark , Cunningham, Julie M. , Wang, Alice H., Asmann, Yan W. , Kay, Neil E. , Doǧan, Ahmet , Witzig, Thomas E. , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 8, 2012 | Volume: 21 | Issue: 10 | Pages: 1799-1806

10.1158/1055-9965.epi-12-0696 | PMID 22911334 Get It

Abstract Background: Non-Hodgkin lymphoma (NHL) is a malignancy of lymphocytes, and there is growing evidence for a role of germline genetic variation in immune genes in NHL etiology. Methods: To identify susceptibility immune genes, we conducted a 2-stage analysis of single-nucleotide polymorphisms (SNP) from 1,253 genes using the Immune and Inflammation Panel. In Stage 1, we genotyped 7,670 SNPs in 425 NHL cases and 465 controls, and in Stage 2 we genotyped the top 768 SNPs on an additional 584 cases and 768 controls. The association of individual SNPs with NHL risk from a log-additive model was assessed using the OR and 95% confidence intervals (CI). Results: In the pooled analysis, only the TAP2 coding SNP rs241447 (minor allele frequency = 0.26; Thr655Ala) at 6p21.3 (OR = 1.34, 95% CI 1.17–1.53) achieved statistical significance after accounting for multiple testing (P = 3.1 × 10−5). The TAP2 SNP was strongly associated with follicular lymphoma (FL, OR = 1.82, 95%CI 1.46–2.26; p = 6.9 × 10−8), and was independent of other known loci (rs10484561 and rs2647012) from this region. The TAP2 SNP was also associated with diffuse large B-cell lymphoma (DLBCL, OR = 1.38, 95% CI 1.08–1.77; P = 0.011), but not chronic lymphocytic leukemia (OR = 1.08; 95% CI 0.88–1.32). Higher TAP2 expression was associated with the risk allele in both FL and DLBCL tumors. Conclusion: Genetic variation in TAP2 was associated with NHL risk overall, and FL risk in particular, and this was independent of other established loci from 6p21.3. Impact: Genetic variation in antigen presentation of HLA class I molecules may play a role in lymphomagenesis. Cancer Epidemiol Biomarkers Prev; 21(10); 1799–806. ©2012 AACR.
Faculty Opinions recommendation of Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Gro
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1088852.541966 Get It

Faculty Opinions recommendation of Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1089765.542900 Get It

Faculty Opinions recommendation of The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1090633.543931 Get It

Faculty Opinions recommendation of Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1105031.561194 Get It

Faculty Opinions recommendation of Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 18, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1111044.574815 Get It